Floatz logo

Romidepsin

Thalassemia

Baylor College of MedicineSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Thalassemia cohort.

Asset / SponsorPhaseRating
Deferasirox
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
Hydroxyurea
Riphah International University
Phase 4BB
Conjugated Pneumococcal Vaccine
Fakultas Kedokteran Universitas Indonesia
Phase 4BB
ZINC SULFATE
Fakultas Kedokteran Universitas Indonesia
Phase 4BB

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →